CGEM

Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing oncology therapies using a diversified portfolio approach. The company advances multiple clinical-stage programs targeting various cancers through different mechanisms of action. Cullinan's pipeline includes novel antibody-drug conjugates, small molecules, and cell therapies designed to address significant unmet medical needs in cancer treatment. The company employs a precision medicine approach, identifying specific patient populations most likely to benefit from its therapies through biomarker-driven strategies. Cullinan Therapeutics was incubated by Cullinan Oncology, which created a portfolio of companies focused on developing transformative cancer treatments. The company collaborates with research institutions and maintains strategic partnerships to advance its programs through clinical development. Cullinan focuses on cancers where existing treatments are inadequate or where resistance to current therapies represents a major challenge. As a clinical-stage company, Cullinan does not yet generate product revenue and focuses on advancing its pipeline through clinical trials toward regulatory approval.